Chief Operating Officer
Bedford Massachusetts UNITED STATES
Sam Rasty, Ph.D., is the Chief Operating Officer of Homology Medicines, having joined the company at its inception in early 2016 and helping to advance it to a publicly traded genomic medicines company in March 2018. He brings together more than 20 years of scientific, clinical, commercial, strategy and business development experience in the life sciences sector across multiple specialty therapeutic areas, rare diseases and technology platforms, spanning from start-up biotechnology to global large pharmaceutical companies. Prior to Homology Medicines, he was Vice President and Head of New Products at the Rare Diseases Business Unit of Shire Pharmaceuticals. In this role, he was positioned at the intersection of Commercial, R&D and Business Development to drive the strategy for growth of the rare disease business through internal product development and external licensing and acquisitions. Before joining Shire, Dr. Rasty’s responsibilities included Corporate Development and Strategic Marketing at Endo Pharmaceuticals as part of the team that drove diversification of Endo’s business through a series of licensing and M&A transactions, and Global Commercial Strategy and Portfolio Management at GlaxoSmithKline within the global R&D organization. Earlier in his career, he held various roles of increasing responsibility in business development and R&D at small, private biotechnology companies. Dr. Rasty holds a Ph.D. in Biochemistry from Louisiana State University, completed his postdoctoral training in Molecular Genetics/Gene Therapy at the University of Pittsburgh School of Medicine and received an M.B.A. from Villanova University.